首页> 美国卫生研究院文献>BMJ Open >Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)
【2h】

Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)

机译:临床监测与抗凝患者突出患者患者分离副肿瘤栓塞:多期式随机安慰剂控制非劣级试验的协议(Safe-SSPE)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clinical significance of subsegmental pulmonary embolism (SSPE) is currently unclear. Although growing evidence from observational studies suggests that withholding anticoagulant treatment may be a safe option in selected patients with isolated SSPE, most patients with this condition receive anticoagulant treatment, which is associated with a 90-day risk of recurrent venous thromboembolism (VTE) of 0.8% and major bleeding of up to 5%. Given the ongoing controversy concerning the risk-benefit ratio of anticoagulation for isolated SSPE and the lack of evidence from randomised-controlled studies, the aim of this clinical trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation in low-risk patients with isolated SSPE.
机译:目前尚不清楚肺栓塞(SSPE)的临床意义。虽然来自观察性研究的越来越多的证据表明,扣留抗凝血治疗可能是孤立的SSPE的选定患者中的安全选择,但大多数这种病症的患者接受抗凝血治疗,其与复发性静脉血栓栓塞(VTE)的90天风险相关(VTE)0.8 %和重大出血高达5%。鉴于持续争议的关于孤立的SSPE抗凝的风险效益比以及随机对照研究中缺乏证据,这项临床试验的目的是评估临床监测的疗效和安全性,而不会在低风险患者中抗凝血孤立的sspe。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号